Comparable stake leader
Citius Pharmaceuticals, Inc.
SEC ownership of CITIUS ONCOLOGY, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001851484.
Disclosed value leader
Citius Pharmaceuticals, Inc.
Comparable rows
20/32
Latest evidence
30 Jun 2026
- Public ticker
- CTOR on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Citius Pharmaceuticals, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
20 of 32
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Citius Pharmaceuticals, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001851484
- Issuer location
- Cranford, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of CITIUS ONCOLOGY, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Citius Pharmaceuticals, Inc.
Disclosed value leader
Citius Pharmaceuticals, Inc.
Comparable rows
20/32
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 71%
12 rows are not safely comparable across share classes.
13D/G row: Citius Pharmaceuticals, Inc.
Showing 1-8 of 32 holder rows.
Quick read
Citius Pharmaceuticals, Inc. leads the comparable SEC ownership view at 71%.
20 of 32 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Citius Pharmaceuticals, Inc.'s linked filing trail.
Comparable ownership
Top 5
Citius Pharmaceuticals, Inc.
71%
ARMISTICE CAPITAL, LLC
10%
BANK OF AMERICA CORP /DE/
4.1%
VANGUARD CAPITAL MANAGEMENT LLC
0.58%
UBS Group AG
0.36%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 32 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. |
13D/G
3/4/5
10%+ Owner
|
71%
|
$59,444,654
66,049,615 shares
|
$0 | 15 May 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
13F
Company
|
10%
|
$6,547,487
9,353,553 shares
|
+$37,545 | 30 Jun 2026 |
| BANK OF AMERICA CORP /DE/ |
13F
Company
|
4.1%
|
$2,492,854
3,835,160 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
0.58%
|
$355,111
546,325 shares
|
— | 30 Jun 2026 |
| UBS Group AG |
13F
Company
|
0.36%
|
$217,502
334,619 shares
|
— | 30 Jun 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.26%
|
$159,538
245,407 shares
|
— | 30 Jun 2026 |
| VANGUARD FIDUCIARY TRUST CO |
13F
Company
|
0.13%
|
$79,242
121,910 shares
|
— | 30 Jun 2026 |
| IFP Advisors, Inc |
13F
Company
|
0.11%
|
$69,836
107,424 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 20 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to CITIUS ONCOLOGY, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
Leonard L. Mazur
Net 12M change
$0
Latest report
10 Aug 2026
Recent insider transactions for CITIUS ONCOLOGY, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jonathan Peri | CTOR | Common Stock | 0 | 0 | 10 Aug 2026 | Direct |
* marks a reported price that did not pass the local price check.